Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders...
Macula EdemaRadiation Retinopathy5 moreThis phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.
Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
Intracerebral HemorrhageCerebral Edema4 moreThe purpose of this study is to test the safety and effectiveness of a single dose of fingolimod in patients with primary spontaneous intracerebral hemorrhage (ICH).
4D-150 in Patients With Diabetic Macular Edema
Diabetic Macular EdemaDiabetic RetinopathyPhase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
A Study to Investigate RO7200220 in Diabetic Macular Edema
Diabetic Macular EdemaStudy BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.
Effect of Enhanced Sweat Rate on the Safety and Edema Status of Chronic Edematous Patients
Chronic Heart FailureThe purpose of this study is to demonstrate safety and performance of AquaPass System for enhancing fluid transfer through the skin, by increased sweat rate, in edematous patients.
Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase...
Diabetic Macular EdemaThis study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).
The Effect of Whole-Body Vibration Treatment Before Total Knee Arthroplasty
Whole-body VibrationArthropathy of Knee1 moreThe study's objective is to investigate the effects of whole-body vibration therapy administered before surgery on various factors related to patients who undergo total knee arthroplasty. These factors include pain, swelling, skin temperature, normal joint movement, knee joint position sense, knee extensor muscle strength, functional status, and patient satisfaction.
Study to Assess Safety and Tolerability of Multiple Doses of EO2002
Corneal EdemaCorneal Endothelial Dystrophy6 moreThe goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.
RO7200220 in Participants With Uveitic Macular Edema
Uveitic Macular EdemaThis study will assess the efficacy and safety of RO7200220 in participants with uveitic macular edema.
Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept
Age Related Macular DegenerationDiabetic Macular Edema2 moreObjective: To determine the association between baseline aqueous cytokine levels and treatment intervals for patients under a variable dosing regimen with intravitreal aflibercept in patients with neovascular age-related macular degeneration (nAMD), macular edema secondary to retinal vein occlusion (RVO) and diabetic macular edema (DME). Methods: A prospective, single-centre study will be performed containing 3 sub-studies according to each study population: nAMD, macular edema secondary to RVO and DME. Inclusion criteria are: patients followed at St. Michael's Hospital with the diagnosis of nAMD, macular edema secondary to RVO or DME. Patients will be excluded if visual acuity is worse than counting fingers, with macular pathologies causing any structural changes to the retina, have received anti-VEGF injections or photocoagulation therapy 6 months prior to study, intraocular surgery 3 months prior to study, any history of vitreoretinal surgery or ocular inflammation in the study eye, use of systemic or topical anti-inflammatory or steroids, patients on dialysis for renal failure, allergy to the study drug or fluorescein, <18 years old, women who are pregnant. All patients will be treated with aflibercept intravitreal injections on a variable dosing regimen: Patients with DME will be examined monthly and receive mandatory injection for the first three months (baseline, weeks 4 and 8). Afterwards, they will continue to be seen monthly and the need for new injections will be decided upon the clinical findings at each visit. An anterior chamber (AC) tap will be done if an injection is required at the visit. Patients with nAMD and RVO will be examined monthly and receive mandatory injection for the first three months. From weeks 12 until 72 (month 18), the visits will be scheduled at increasing 2-weeks intervals based on the stability of the ocular condition and response to treatment. At each visit, an injection and AC tap will be performed. The maximum interval in between injections is 12 weeks. If the disease becomes unstable, the interval in between injections is shortened and, once it stabilizes, the treatment frequency is extended again. In all patients, baseline aqueous humour specimens will be obtained prior to the first aflibercept intravitreal injection and follow-up samples will be taken immediately prior to subsequent injections based on the treatment regimens for cytokine analysis in the end of the follow-up.